{
    "clinical_study": {
        "@rank": "55338", 
        "arm_group": [
            {
                "arm_group_label": "Valsartan 160mg, Rosuvastatin 20mg", 
                "arm_group_type": "Experimental", 
                "description": "Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks."
            }, 
            {
                "arm_group_label": "Valsartan 160mg, Rosuvastatin 20mg placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks."
            }, 
            {
                "arm_group_label": "Valsartan 160mg placebo, Rosuvastatin 20mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intervention : Drug : Both Valsartan 160mg placebo  and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to evaluate the efficacy and safety of the coadministration of valsartan\n      (Diovan\u00ae) 160mg and rosuvastatin (Crestor\u00ae) 20mg in comparison to each component\n      administered alone in patients with hypertension and hyperlipidemia."
        }, 
        "brief_title": "Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hypertension,", 
            "Hyperlipidemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipidemias", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient aged 20-80 years who has hypertension and hyperlipidemia\n\n          2. Patient who has a Hypertension\n\n          3. Patient who has a Hyperlipidemia according to NCEP-ATP III guideline(2004)\n\n          4. Patient who signed the Informed Consent Form after receiving an explanation on the\n             purpose, methods, and effect of the study\n\n        Exclusion Criteria:\n\n          1. If blood pressure and fasting serum lipid level measured at screening and Visit 2 (0\n             week) satisfy the following criteria 1) sitSBP\u2265180mmHg or  sitDBP\u2265110mmHg (For high\n             risk group,  sitSBP\u2265 160mmHg or sitDBP \u2265100mmHg ) 2) LDL-C>250mg/dL , or TG\u2265 400mg/dL\n\n          2. If sitSBP difference between the right and left arms >20mmHg or sitDBP difference\n             between the right and left arms > 10mmHg at screening\n\n          3. When blood pressure is repeatedly measured from the selected arm at screening, if\n             sitSBP difference \u2265 20mmHg  or sitDBP difference \u226510mmHg\n\n          4. Patient with orthostatic hypotension accompanying symptoms at screening (decrease in\n             sitDBP \u226510mmHg or decrease in sitSBP \u2265 20mmHg )"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "168", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918332", 
            "org_study_id": "LG-VRCL002"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Valsartan 160mg, Rosuvastatin 20mg", 
                    "Valsartan 160mg, Rosuvastatin 20mg placebo"
                ], 
                "intervention_name": "Valsartan 160mg", 
                "intervention_type": "Drug", 
                "other_name": "Diovan"
            }, 
            {
                "arm_group_label": [
                    "Valsartan 160mg, Rosuvastatin 20mg", 
                    "Valsartan 160mg placebo, Rosuvastatin 20mg"
                ], 
                "intervention_name": "Rosuvastatin 20mg", 
                "intervention_type": "Drug", 
                "other_name": "Crestor"
            }, 
            {
                "arm_group_label": [
                    "Valsartan 160mg placebo, Rosuvastatin 20mg", 
                    "Placebo"
                ], 
                "intervention_name": "Valsartan 160mg placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Valsartan 160mg, Rosuvastatin 20mg placebo", 
                    "Placebo"
                ], 
                "intervention_name": "Rosuvastatin 20mg placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Valsartan", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Yonsei University Health System Severance Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multicenter, Randomized, Factorial, Double-blinded, Double-dummy Phase \u2162 Trial to Evaluate the Efficacy and Safety of the Coadministration of Valsartan 160mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone in Patients With Hypertension and Hyperlipidemia.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "sitDBP changes of the valsartan+rosuvastatin and rosuvastatin alone groups at Week 8 from baseline", 
                "measure": "sitDBP changes at Week 8 from baseline", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "LDL-C percentage changes of the valsartan+rosuvastatin and valsartan alone groups at Week 8 from baseline", 
                "measure": "LDL-C percentage changes at Week 8 from baseline", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918332"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}